Cardiovascular Safety with RA Treatments

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022 Jan 27;386(4):316–326.
Safety study of tofacitinib vs. tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis (NCT02092467). ClinicalTrials.gov. 2021 Aug 17.
Supplement approval letter: Xeljanz (tofacitinib). U.S. Food & Drug Administration. 2021 Dec 2.
Chicre D, Pugliesi A, Bértolo MB, et al. Compared mortality and cardiovascular safety of jak inhibitors and tocilizumab in patients with RA: A systematic review and network meta-analysis [abstract 0284]. Arthritis Rheumatol. 2022 Oct; 74 (suppl 9).

ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…

A decade after JAK inhibitors were approved, this EULAR 2022 session looks at whether the drugs have lived up to expectations.

On Sept. 1, the U.S. Food & Drug Administration (FDA) announced that it is requiring revisions to the Boxed Warning for the Janus kinase (JAK) inhibitors Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib) and Rinvoq (upadacitinib) to include information about the risks of serious heart-related events, cancer, blood clots and death.1 Recommendations for healthcare professionals will include…

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

References

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

JAK Inhibitors: Are All Promises Fulfilled?

FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

References

Related Articles